Hadassah

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Monday, Aug 14 2017

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

CDI, often also called C. difficile, is caused by a bacterial toxin that inflames the colon. It is especially found in hospitals and long-term, in-patient care facilities. Approximately 500,000 people annually contract CDI in the U.S. alone and about 20 percent experience a recurrence.

The new product, called IMM-529, is a naturally produced biological antibody, intended to prevent and treat CDI, as well as stop recurrence. As a polyclonal antibody, it generates highly specific antibodies to fight the three main sources of CDI: Toxin B, the highly infectious spores, and the vegetative cells in the gut. In addition, IMM-529 has been shown to rebalance the diversity of bacteria in the gut, which is often disrupted by antibiotics.

This first-ever human study will assess whether IMM-529 is safe and well tolerated by the participants and will also evaluate the preliminary efficacy of IMM-529. Pre-clinical studies with mice at Monash University in Melbourne, Australia, revealed 80 percent efficacy in preventing and treating CDI and 77.8 percent success in preventing recurrence. The control group of mice, in contrast, which only received the standard-of-care antibiotic, vancomycin, experienced a mortality rate of 88.9 percent.

In this human trial, 60 patients who have been diagnosed with CDI and treated with standard-of-care antibiotics, will be enrolled within three weeks of their diagnosis. Some will be randomly selected to receive IMM-529 three times daily and the others will receive a placebo for 28 days.

Read more at: http://www.immuron.com/assets/Uploads/Red-Chip-C-Difficile-Analyst-Report-Jan-2016.pdf

Read about another IMMURON clinical trial at Hadassah http://www.hadassah.org/news-stories/fatty-liver-us-trials.html

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, May 16 2019

First of Its Kind in Israel: Cardiac Catheterization at Hadassah on Under Two-Pound Baby

A cardiac catheterization, the first of its kind in Israel, was successfully performed this week at Hadassah Hospital Ein Kerem on a fragile premature infant, weighing under two pounds.

READ MORE ›
alt_text

Wednesday, May 15 2019

How Much Do You Know About Your Liver and Hadassah’s Life-Saving Liver Treatments?

Three pounds of reddish-brown tissue tucked under the diaphragm, your liver churns out over 1,000 different types of enzymes to help you digest food, store energy, and wash out toxins

READ MORE ›
alt_text

Monday, May 13 2019

Grappling with Life Post-Trauma: Hadassah Therapist Offers Advice

As we return to normal life in the aftermath of terror attacks, whether in synagogues, churches, or other settings in our local communities, how do we cope?

READ MORE ›
alt_text

Thursday, May 9 2019

When Gender Is Ambiguous

Under the cover of darkness, an Arab family left Gaza for Hadassah Hospital Ein Kerem. Little Noor would return as little Ahmed.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More